Associations of Genetic Variants in the Dopamine Transporter with Problematic Sexual Behavior and Reward Deficiency Syndrome

Authors

Shui Jiang, PhD

Jerome C. Foo, PhD

Xiuying Hu, BM, MSc

Bradley Green, PhD

Randolph Arnau, PhD

Pennie J. Carnes, MA

Behavioral Addictions Studies and Insights Consortium*

Rick Isenberg, MD

David Wishart, PhD

Patrick J. Carnes, PhD

Esther Fujiwara, PhD

Katherine J. Aitchison, BM BCh, PhD, FRCPsych

Affiliations

Department of Psychiatry, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB, Canada (SJ, JCF, EF, KJA); Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Mannheim, Germany (JCF); Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada (JCF, KJA); Department of Medical Genetics, Faculty of Medicine and Dentistry, College of Health

CONFIDENTIAL

Sciences, University of Alberta, Edmonton, AB, Canada (XH, KJA); Department of Psychology and Counseling, University of Texas at Tyler, Tyler, TX, USA (BG); School of Psychology, University of Southern Mississippi, Hattiesburg, MS, USA (RA); Gentle Path at the Meadows, Wickenburg, AZ, USA (PJC, PJC); Psychological Counselling Services., Scottsdale, AZ, USA (RI); Department of Biological Sciences, Faculty of Science, College of Natural and Applied Sciences, University of Alberta, Edmonton, AB, Canada (DW); Women and Children's Health Research Institute, University of Alberta, Edmonton, AB, Canada (KJA); and the Psychiatry Section, Division of Clinical Sciences, Northern Ontario School of Medicine, Thunder Bay, ON, Canada (KJA)

Correspondence to:

Shui Jiang, PhD

Tel number: 780-492-4018

Email: shui2@ualberta.ca

5-020, Katz Group Centre for Pharmacy and Health Research, Edmonton, AB, Canada

***Consortium authors in supplementary material**

Sources of support/funding for the work

The work herein was supported by an Alberta Centennial Addiction and Mental Health Research Chair and transitional funding (to KJA), Canada Foundation for Innovation (CFI), John R. Evans Leaders Fund (JELF) grant (32147 - Pharmacogenetic translational biomarker discovery), Alberta Innovation and Advanced Education Small Equipment Grants Program (to KJA), and a

CONFIDENTIAL

research grant and philanthropic support from the American Foundation for Addiction Research (to KJA). A Fulbright-Canada-Palix Foundation grant (to PJC) assisted with his contributions to study design, project management, and collaborative working. SJ was supported by an Alberta Innovates Postdoctoral Recruitment Fellowship.

Conflicts of interest:

While PJC was previously a Board member of the American Foundation for Addiction Research, he is no longer a member. Moreover, neither the Foundation nor any other of the funders played any role in study design, or in data analysis or interpretation thereof. All other authors declare no conflicts of interest.

Abstract word count: < 250 (247)

Manuscript word count (not including references, tables, or figure legends): <3500 (3461)

Number of references: <40 (39)

CONFIDENTIAL

ABSTRACT

Objectives

Problematic sexual behavior (PSB) is defined by recurrent sexual behaviors that are difficult to control, causing social and functional impairments. PSB can co-occur with reward deficiency syndrome (RDS), but this relationship remains unclear. RDS has been associated with the 10/10 genotype of 3' variable number tandem repeat (VNTR) in the dopamine transporter gene *SLC6A3,* which is implicated in the reward pathway. This study investigates the genetic relationship between PSB and RDS, testing their association with *SLC6A3* 3' VNTR genotype.

Methods

PSB patients from addiction treatment facilities (n=454), and comparison participants (with PSB=82; without PSB, n=888) were recruited. PSB was measured by the Sexual Addiction Screening Test-Revised (SAST-R) Core and RDS was measured using a composite variable from a custom test battery. DNA was collected from saliva and buccal swabs. Genotyping was performed using polymerase chain reaction (PCR), and regression analyses were conducted to investigate the association of *SLC6A3* 3' VNTR genotype with PSB and RDS.

Results

The 10/10 genotype of *SLC6A3* 3' VNTR was associated with RDS in a combined analysis of all groups, and with PSB only in comparison participants. In patients, rare *SLC6A3* 3' VNTR genotypes (3-, 6-, 8-, 11-repeat alleles) were associated with PSB. No genotype showed relationships to RDS in only PSB patients.

Conclusions

CONFIDENTIAL

The link of the 10/10 genotype to RDS indicates that PSB could be a manifestation of RDS in non-clinical populations; rare genotypes might be associated with clinical forms of PSB, together with comorbid psychopathology.

Keywords: addiction; behavioral addiction; reward deficiency syndromes; genetics; the dopamine transporter gene

CONFIDENTIAL

1. INTRODUCTION

Problematic sexual behavior (PSB) is defined as difficult to control recurrent sexual behaviors that cause social and functional impairments.[1] PSB can be referred to as sex addiction,[2] or compulsive sexual behavior.[3] The scientific debate on the nosology and nature of PSB continues, but it is recognized that PSB often co-occurs with neuropsychiatric conditions such as reward deficiency syndrome,[4,5] possibly suggesting common underlying biology.

Reward deficiency syndrome (RDS), often described as an "octopus of behavioral dysfunction," is not a single mental health condition, but a collection of conditions including addictive, compulsive, and impulsive behaviors, and personality disorders, which share endophenotypes characterized by hypodopaminergia in the reward circuit.[6-8] Although the relationship between RDS and PSB is not well characterized, there is emerging evidence that they may overlap.[1] Jiang et al. (2023) reported that compared to those without PSB, university students with PSB showed significantly higher rates of conditions with known alterations in the dopaminergic reward pathway which would fall under the umbrella of RDS (e.g., Attention Deficit/Hyperactivity Disorder [ADHD], obsessive-compulsive disorder [OCD], and personality disorders).[1]

Addictive behaviors and symptoms are core features of RDS,[9] and there are several genetic variants associated with vulnerability, maintenance, and relapse in addiction.[10-12] It is possible that at least part of the phenotypic overlap between PSB and RDS may be driven by genetic variants common to the two. For example, in one study, 81% of sexual addiction patients reported that at least one parent had an addictive disorder, with 36% indicating that a parent had a sexual addiction.[13] One of the potential genetic variants for addictive disorders is the dopamine transporter gene *SLC6A3 (solute carrier family 6 member 3)*, located at chromosome 5p15.33.

CONFIDENTIAL

111 There is a 40-base pair variable number tandem repeat (VNTR) in the 3' untranslated region of
112 *SLC6A3* with 9- and 10- repeat alleles being the most common.[14] Studies have shown that
113 individuals with the *SLC6A3* 10/10 genotype express higher levels of dopamine transporter than
114 9-repeat allele carriers, and this is reflected in lower striatal dopamine among 10-repeat
115 carriers.[15]

116 The dopamine transporter mediates the reuptake of dopamine from the synaptic cleft,[16]
117 and the 10/10 genotype of the *SLC6A3* 3' VNTR has been implicated in various conditions
118 associated with an altered reward system, including ADHD and addictive disorders.[12,17,18] For
119 example, Cornish et al. (2005) reported that the 10/10 genotype was associated with higher
120 ADHD symptom scores in boys.[19] A meta-analysis by Ma et al., (2016) showed that individuals
121 carrying the 10/10 genotype were 17% less likely to quit smoking compared to those who was
122 the 9-repeat alleles.[10] Furthermore, a previous study indicated that the 10-repeat allele of the
123 *SLC6A3* 3' VNTR was associated with phenotypes directly related to sexual behavior. In a study
124 of men, Guo et al. (2007) reported that individuals with at least one 10-repeat allele of the
125 *SLC6A3* 3' VNTR showed an 80%-100% increase in the number of sexual partners compared to
126 those homozygous for the 9-repeat allele.[20,21] While the 10/10 variant seems to be more
127 consistently identified as the risk genotype, some studies probing gene-environment (G×E)
128 interactions pointed to a greater sensitivity of 9-repeat carriers to environmental influences. For
129 example, Erblich and colleagues (2004) reported that after stress, carriers of the 9-repeat allele
130 showed a cigarette craving four times greater than non-carriers.[22] This contrasts with findings of
131 potentially protective effects of the 10-repeat variant under adverse environmental influences
132 (stress or childhood trauma) as seen in ADHD,[19] smoking,[10] and number of sexual partners.[20,21]

CONFIDENTIAL

133 However, these complex interactions have rarely been explored and contradictory findings exist
134 as well.[23]

135 Apart from common alleles such as 9- and 10-repeat, rare genetic variants, such as 3-, 5-,
136 7- , 8-, and 11-repeats are also observed.[14] Despite their low frequency and smaller contribution
137 to population-wide heritability compared to common variants, these rare variants can still
138 significantly increase individual risk of illness due to their pronounced impact on protein
139 function or expression.[24] A previous study including 471 children with or without ADHD found
140 that *SLC6A3* rare genotypes (8/10, 7/10 and 10/11) were associated with ADHD.[25] However,
141 research on these rare genotypes in candidate gene studies is limited, and these variants have
142 often been excluded due to their low frequency and the resulting small sample sizes.

143 The aim of the present study was to investigate the relationship between PSB and RDS at
144 the candidate gene level in PSB patients and in a non-clinical sample, with a focus on *SLC6A3*
145 3'VNTR genotype. We expected to extend the association between PSB and RDS that we had
146 previously reported in the non-clinical comparison participants to a clinical sample. We
147 hypothesized that the 10/10 genotype might be associated with PSB and/or with RDS.

148

149 **2. METHODS**

150 **2.1.Patients and comparison participants**

151 The clinical cohort comprised inpatients and outpatients receiving treatment for PSB at eight
152 addiction treatment facilities in the United States (n=512). The recruitment of comparison
153 participants (n=3530) was undertaken at a Canadian university as previously described.[1] Since
154 the allele frequencies of the *SLC6A3* 3' VNTR are observed to vary by ethnicity,[26] genotypic and

CONFIDENTIAL

155 phenotypic analyses were restricted to individuals of European ancestry (n=1434, Supplemental
156 Digital Content, Figure 1).
157 All participants provided written informed consent. The Quorum Review Institutional
158 Review Board (Seattle, Washington; Protocol Number: 2016-001) and the University of Alberta
159 Research Ethics Board (Protocol: Pro00066552) approved the study.

160 **2.2.Assessments**

161 We screened for PSB with the 20-item Sexual Addiction Screening Test-Revised (SAST-R)
162 Core.[27] We measured four addictive dimensions of PSB: relationship disturbance caused by
163 sexual behaviors (SAST-R Core items 6, 8, and 16, and we also included item 26 from the
164 additional SAST-R subscales[27]), loss of control despite problems (SAST-R Core items 10, 12,
165 15, and 17), preoccupation about sex (SAST-R Core items 3, 18, 19 and 20), and affect
166 disturbance (such as anxiety and depression related to sexual behaviors, SAST-R Core items 4,
167 5, 11, 13 and 14). Each question is responded to with a binary choice (yes/no=1/0), and the
168 threshold for screening positive for PSB in the general population is 6.[27] The PSB variable we
169 used in all analyses (referred to as the "adjusted SAST-R Core") was the scale total minus the
170 first two questions, which inquire about a history of childhood sexual trauma and parental
171 trouble with sexual behavior, as previously described.[1] These items were excluded due to their
172 overlap with other variables in our analysis, such as "self-reported childhood trauma" and
173 "family history of PSB." This approach was taken to avoid redundancy and increase the
174 specificity of the PSB regression, even though there are a part of SAST-R Core.
175 To derive our RDS measure, several relevant conditions were assessed, including
176 nicotine dependence (Fagerström Test for Nicotine Dependence [FTND]), pathological gambling
177 (DSM-5 Pathological Gambling Diagnostic Form [DPGDF]), personality disorders (8-item

CONFIDENTIAL

178 Standardized Assessment of Personality-Abbreviated Scale as a Self-Administered Screening
179 Test [SA-SAPAS]), ADHD (Adult ADHD Self-Report Scale [ASRS] version 1.1), compulsive
180 buying (Richmond Compulsive Buying Scale [RCBS]), and internet addiction (Internet
181 Addiction Test [IAT]), as previously described.[1] To represent the overall RDS construct, a
182 dummy coded binary variable was created (1=positive screening in any of the RDS components,
183 0=no). In addition, we collected self-reported information about demographic details, childhood
184 trauma (self-reported childhood physical, emotional and sexual trauma, and family history of
185 domestic violence, combined with item 1 from the SAST-R Core "sexually abused as a child",
186 1=yes, 0=no, as previously described[1]), past or current mental health diagnoses (1=yes, 0=no),
187 number of past or current mental health diagnoses, and number of mental health condition(s) in
188 the family history. A positive family history of PSB (1=yes, 0=no) was ascertained through item
189 2 of the SAST-R Core ("parental problems with sexual behavior") and self-report data, as
190 previously described.[1] Since OCD in particular is reported to be associated with PSB[1] and RDS,[4]
191 we also used available data from MINI-International Neuropsychiatric Interview (MINI) (n=715;
192 379 comparison participants without PSB, 72 comparison participants with PSB, 264 patients),
193 in combination with self-reported past/current OCD diagnoses (n=967, 448 comparison
194 participants without PSB, 89 comparison participants with PSB, 430 patients) to estimate rates of
195 OCD.

196 **2.3. Genotyping**

197 DNA was extracted from saliva using Oragene OG-500 kits (DNAGenotek, Kanata, Canada)
198 and/or from buccal swabs (Isohelix via D-Mark Biosciences, Toronto, Canada). Genotyping of
199 the 40 bp *SLC6A3* 3' VNTR was performed by a polymerase chain reaction (PCR). DNA was
200 amplified with an initial denaturation step at 95°C for 2 minutes, followed by 35 cycles of

CONFIDENTIAL

201 denaturation at 95°C for 15 seconds, annealing at 64°C for 30 seconds, extension at 72°C for 1
202 minute, and a terminal extension step of 72°C for 5 minutes (modified from Vandenbergh et al.,
203 1992).[14] The primer sequences were: forward 5'-TGTGGTGTAGGGAACGGCCTGAG-3', and
204 reverse 5-CTTCCTGGAGGTCACGGCTCAAGG-3'.[14] PCRs were resolved on a 2.25% agarose
205 gel. The 9-repeat number was at 440 bp and the 10-repeat number was at 480 bp on the gel;
206 genotypes other than 9/9, 9/10, or 10/10 are considered rare genotypes.[14] Since the allele
207 frequencies of the *SLC6A3* 3' VNTR vary by ethnicity,[26] genotypic and phenotypic analyses
208 were conducted in only those of European ancestry.

209 **2.4.Data analysis**

210 Data were analyzed using STATA.[28] To examine the association of PSB, participants were
211 categorized into three groups: (1) PSB patients (n = 405; patients who scored ≥11 on the
212 unadjusted SAST-R Core); (2) Comparison participants with PSB (n=85) scoring ≥6 on the
213 unadjusted SAST-R Core,[27] and (3) Comparison participants without PSB (n=439) scoring <6 on
214 the unadjusted SAST-R Core and also screening negative on other relevant measurements.[27]
215 In the final analysis of PSB, a total of 929 participants (524 from the comparison group
216 and 405 from the patient group) were included, after the removal of 59 individuals who were not
217 of European ancestry or did not provide DNA. The SAST-R Core, developed based on a large
218 clinical cohort (665 men and 274 women) of inpatients and outpatients in treatment for PSB,
219 classifies individuals at a cut-point of 6, achieving a sensitivity of 0.817 and specificity of
220 0.778.[27,29] However, to enhance the specificity of the genetic association study, we selected a
221 cut-off score of 11 on the SAST-R Core to focus on individuals with more pronounced PSB
222 symptoms. This stricter threshold was implemented to ensure clearer signals for the genetic
223 analysis by minimizing ambiguous cases, thereby prioritizing the identification of true positives

CONFIDENTIAL

224 over the risk of false negatives. Thus, we excluded 19 patients who scored <11 on the unadjusted
225 SAST-R Core.[28,29] In addition, to enhance the specificity of testing for associations with PSB, we
226 excluded a total of 432 participants who screened negative for PSB, but positive for RDS or
227 mental health conditions(s). This was done due to the consideration of potentially shared genetic
228 etiologies between RDS, PSB, and mental health conditions. For the validation of RDS, all
229 available data from patients (n=376) and comparison participants (n=668) were included.

230 **2.4.1. Descriptive statistics**

231 To investigate if those with or without PSB have different clinical and demographic features,
232 group differences were examined with Pearson's χ^2 test or a Mann-Whitney *U* test or a Kruskal-
233 Wallis test, followed by Dunn's test. To test if the distribution of *SLC6A3* genotype differed
234 between different groups, Pearson's χ^2 was conducted. Tetrachoric (for binary variables) and
235 Kendall's τ (for ordinal variables) correlations were used to examine the correlation of clinical
236 and demographic variables with severity of PSB.

237 **2.4.2. Regression analyses**

238 To investigate the association of demographic and clinical variables with PSB and RDS,
239 backward stepwise logistic regressions were performed. Regarding PSB, two regression models
240 were performed: the first model included all comparison participants (with and without PSB), the
241 second model included PSB patients and comparison participants without PSB. Initial
242 independent variables in both models were: age, gender, *SLC6A3* genotype, childhood trauma,
243 self-reported mental health condition(s) (a binary variable), number of mental health condition(s)
244 in the family history (a continuous variable), and family history of PSB or of OCD. We also
245 included an interaction term of childhood trauma and *SLC6A3* genotype to test for potential G×E
246 interactions.[23,30,31] To validate the association of the 10/10 genotype with RDS, one regression

CONFIDENTIAL

247 model was applied using the entire cohort. Initial independent variables were identical but
248 additionally included "group" (comparison participants vs. patients). Predictors were retained in
249 the models if the model passed the link test for correct specification and showed non-significant
250 Hosmer-Lemeshow χ^2, their inclusion did not introduce multicollinearity, and they remained
251 significant in the final model. A *P*-value of <0.05 was considered significant.

252 **3. RESULTS**

253 A total of 8.5% of comparison participants (82 out of 970) scored ≥ 6 on the unadjusted SAST-R
254 Core, meeting the threshold for PSB in the general population.[23] Patients showed the highest
255 scores in adjusted SAST-R Core and addictive dimensions of PSB (*P*<0.001, Table 1).
256 Compared to comparison participants, patients were significantly older (*P*<0.001), had a higher
257 proportion of male participants, and higher rates of RDS (*P*<0.001, Table 1). Furthermore,
258 family history of mental health condition(s) and experiencing childhood trauma increased in
259 frequency from comparison without PSB to comparison with PSB to PSB patients (*P*<0.001,
260 Table 1).

261 The distributions of *SLC6A3* genotypes (9/9, 9/10, and 10/10) were in Hardy-Weinberg
262 Equilibrium in both comparison participants and in patients (Supplemental Digital Content,
263 Table 1). Results showed that comparison participants with the 10/10 genotype had trend level
264 elevated rates of PSB compared to 9-repeat carriers (*P*=0.050, Table 2). They also displayed
265 significantly higher RDS total scores (*P*=0.0042), especially regarding ADHD symptoms
266 (ASRS, *P*=0.021) and internet addiction (IAT, *P*=0.0073), followed by a trend level elevation in
267 compulsive buying (RCBS, *P*=0.050).

268 In comparison participants, the 10/10 genotype showed trend level correlations with RDS
269 (τ=0.077, *P*=0.088), with self-reported mental health condition(s) (τ=0.081, *P*=0.073), as well as

CONFIDENTIAL

270 with PSB (τ=0.082, *P*=0.067; Supplemental Digital Content, Figure 2). In patients, however, the
271 10/10 genotype was not significantly correlated with PSB or RDS. Our results higher rates of
272 OCD in *SLC6A3* 3' VNTR rare genotype carriers (*P*=0.044, Table 2). Additional analyses on
273 correlations between genotype and SA-SAPAS items are shown in Supplemental Digital
274 Content, Table 2.

275 **3.1.Regression analyses**

276 In both regression models for PSB, *SLC6A3* genotype, childhood trauma, family history of PSB,
277 and gender were retained as independent variables (Model 1 in comparison participants: pseudo
278 R^2=0.12, n=509, Figure 1; Model 2 in PSB patients and comparison participants without PSB:
279 pseudo R^2=0.58, n=739, Figure 2). In Model 1, the 10/10 genotype of *SLC6A3* 3' VNTR (OR:
280 1.97, 95% confidence interval (CI): 1.15-3.38, *P*=0.013), childhood trauma (OR: 2.31, 95% CI:
281 1.21-4.41, *P*=0.011), family history of PSB (OR: 4.49, 95% CI: 1.85-10.90, *P*<0.001) and male
282 gender (OR: 4.54, 95% CI: 2.64-7.83, *P*<0.001) were associated with PSB. In Model 2, *SLC6A3*
283 3' VNTR rare genotypes (OR: 5.69, 95% CI: 1.08-30.07, *P*=0.041), childhood trauma (OR: 9.78,
284 95% CI: 4.91-19.49, *P*<0.001), family history of PSB (OR:45.65, 95% CI: 15.56-133.90,
285 *P*<0.001), and male gender (OR: 142.77, 95% CI: 52.11-391.15, *P*<0.001) were associated with
286 PSB. The 10/10 genotype was not significantly associated with PSB in model 2 (*P*=0.72). The
287 interaction term of childhood trauma and *SLC6A3* genotype was not significant in either
288 comparison participants (*P*=0.36) or in patients (*P*=0.26).

289 For RDS, the final model retained the interaction term of *SLC6A3* genotype and
290 childhood trauma, self-reported mental health condition(s), *SLC6A3* genotype, childhood trauma,
291 and group status on the entire cohort (pseudo R^2=0.13, n=1044, Figure 3). Significant parameters

CONFIDENTIAL

292 included the 10/10 genotype of *SLC6A3* 3' VNTR (OR:2.39, 95% CI:1.52-3.77, $P<0.001$), self-
293 reported mental health condition(s) (OR:2.64, 95% CI: 1.96-3.56, $P<0.001$), childhood trauma
294 (OR:2.81, 95% CI:1.72-4.60, $P<0.001$), and being a PSB patient (OR:4.10, 95% CI:2.96-5.68,
295 $P<0.001$). The interaction term of the 10/10 genotype and childhood trauma was significantly
296 associated with decreased odds of RDS (OR:0.32, 95% CI:0.17-0.60, $P=0.011$, the detailed
297 interaction terms and predicted margins are provided in Supplemental Digital Content, Table 3).

298 **4. DISCUSSION**

299 In our study, the 10/10 genotype of the SLC6A3 3' VNTR was associated with PSB in healthy
300 young adults, and with RDS across the entire cohort, suggesting that this genotype may serve as
301 a shared genetic risk factor for both PSB and RDS. This indicated that PSB could be a
302 manifestation of RDS in this cohort of healthy young adults. However, in the clinical cohort, it
303 was rare genotypes, rather than the 10/10 genotype, that showed the association to PSB. This
304 observation aligns with the understanding that both common and rare genetic variants can be
305 associated with a psychiatric phenotype, with common genotypes typically exerting a smaller
306 impact, while rare genotypes tend to have a larger impact and are associated with more severe
307 symptoms.[24]

308 Whether PSB should be regarded as a behavioral addiction or compulsive disorder
309 remains an open question.[32,33] Of note, Koob and colleagues (2016) conceptualized addiction as
310 a cycle with three stages, linked to disruptions in dopaminergic and serotoninergic pathways.[34]
311 They further indicated that impulsivity is often seen in the early stages of addiction, and
312 compulsivity evolves as the condition progresses.[34] Impulsive, reward-seeking tendencies of
313 PSB[31,32] could be more prominent in milder forms of PSB, such as in the comparison group, and

CONFIDENTIAL

appear to be associated with the relatively common 10/10 VNTR genotype. In contrast, the compulsive features may prevail in clinical PSB, accompanied by multiple mental health comorbidities (e.g., OCD), and then be associated with rare VNTR genotypes.

Through our convenience sampling we were not able to match comparison participants and PSB patients on age and other demographic variables. These group differences could have driven different manifestations of PSB, which may be associated with different genetic risk factors. Riemersma et, al. (2013) proposed a "new generation of sex addiction," or "comtemporary sex addiction." While both "classical sex addiction" and "contemporary sex addiction" could be assaociated with alterations in the reward pathway, Riemersma et, al. (2013) suggested that "contemporary sex addiction" is primarily linked to reward seeking, whereas "classical sex addiction," is predominantly associated with trauma, emotional dysregulation, and insecure attachment, and may involve alterations in the prefrontal and limbic regions.[35,36] In our study, comparison participants with PSB were significantly younger and a lower ratio of them reporting childhood trauma than PSB patients. Hence, the relevance of the 10/10 genotype to RDS in the entire cohort might have been influenced by the larger proportion of younger participants who could have had such "contemporary" PSB. In contrast, rare genotypes of the *SLC6A3* 3' VNTR, higher rates of childhood trauma and mental health comorbidities such as OCD could potentially be associated with more "classical" sex addiction in the clinical PSB group. Interestingly, our results suggest that in patients, this VNTR may have a potential link to OCD, with those who carried rare genotypes having higher rates of OCD. Some previous research has suggested a potential association between this VNTR and OCD;[37,38] however, further studies are needed to confirm these associations.

CONFIDENTIAL

336 We also investigated specific G×E interactions (*SLC6A3* 3' VNTR genotype and
337 childhood trauma) in the context of hypodopaminergic phenotypes of PSB and RDS. Although
338 such interactions have been explored in some relevant psychiatric conditions, particularly in
339 substance use, the results have been inconsistent or inconclusive.[23] A systematic review
340 examining G×E between dopaminergic genes (*DRD2*, *DRD4*, and *SLC6A3*) and psychological,
341 family, and socio-demographic factors in relation to substance abuse reported that five out of
342 nine studies identified at least one significant interaction.[23] In the present study, we observed that
343 the 9-repeat allele could be associated with RDS when childhood trauma was present. It is
344 possible that the 9-repeat allele carriers may be more sensitive to environmental influences. For
345 example, other research has found that children with conduct disorder and the 9/9 genotype
346 showed stronger reductions in symptom severity in response to both negative or positive
347 parenting practices, compared to 10-repeat allele carriers.[31]

348 This study had several limitations and the sociodemographic differences between the
349 comparison participants and patients in these convenience samples are important to
350 acknowledge. As mentioned above, age influences the phenotype and genetic susceptibility to
351 many psychiatric symptoms, presumably including PSB and RDS.[35,39] Furthermore, the analysis
352 was limited to those of European ancestry and included relatively few women. Also, the sample
353 size for rare genotypes was limited, making it challenging to investigate the differential
354 phenotypes between common and rare genotypes. Additionally, only one genetic variant in the
355 *SLC6A3* gene and only one gene in the dopaminergic pathway were investigated in this study. It
356 is possible that other genes, gene-gene interactions and G×E interactions may be associated with
357 PSB and could have impacted the results. Thus, the findings should be interpreted with caution,
358 and sample recruitment and matching should be optimized in future studies. These should also

CONFIDENTIAL

incorporate a broader range of common genetic variants or use a genome-wide approach, which would offer deeper insights into the genetic foundations of PSB.

5. CONCLUSION

Our results suggest that both common and rare variants of *SLC6A3* may be associated with PSB. The link of the 10/10 genotype to RDS indicates that PSB could be a manifestation of RDS in comparison participants, whereas rare *SLC6A3* variants might be associated with clinical PSB, together with comorbid mental health issues.

CONFIDENTIAL

6. Acknowledgement

The authors would like to express their gratitude to all those who supported data collection at the university: Keanna Wallace, Esther Yang, Leslie Roper, Garima Aryal, Dawon Lee, and Rohit J Lodhi.

CONFIDENTIAL

370 **Figure 1. Forest Plots of Problematic Sexual Behavior (PSB) Logistic Regression Analysis**

371 **in Comparison Participants**

372



373

374

375 By logistic regression. The log likelihood of the model was -192.24 (n = 509, with 5 outliers

376 removed, with a pseudo $R^2 = 0.12$, $P<0.001$). The model passed the link test with a significant

377 *P*(hat) (P=0.0080) and a nonsignificant *P*(hatsq) (P=0.66). The probability of the Hosmer-

378 Lemeshow $\chi 2$ test was insignificant (P=0.75), suggesting good model fit. The mean VIF and the

379 condition number were 1.06 and 3.38, respectively. The model accuracy, area under the ROC

380 curve, sensitivity, specificity, and F score were 85.07%, 73.87%, 3.90%, 99.54%, and 0.073,

381 respectively. The exact *P*-values were as follows: family history of PSB ($P=9.19\times10^{-4}$), gender

382 (men: $P=5.17\times10^{-8}$). Power analysis demonstrated that the regression model had a power of over

383 0.90. *Abbreviation: PSB: problematic sexual behavior; SLC6A3: solute carrier family 6 member*

384 *3; VIF: variance inflation factor.*

CONFIDENTIAL

385 **Figure 2. Forest Plots of Problematic Sexual Behavior (PSB) Logistic Regression Analysis**

386 **in Patients and Comparison Participants Without PSB**

387



388

389

390 By logistic regression. The log likelihood of the model was -195.53 (n=739, after removing

391 outliers, n=105, with 102 having PSB, and with a pseudo R^2=0.58, P<0.001). The model passed

392 the link test with a significant P(hat) (P<0.001) and a nonsignificant P(hatsq) (P=0.56). The

393 probability of the Hosmer-Lemeshow $\chi 2$ test was insignificant (P=0.98), suggesting a good

394 model fit. The mean VIF and the condition number were 1.60 and 4.18, respectively. The model

395 accuracy, area under the ROC curve, sensitivity, specificity, and F score were 85.39%, 94.03%,

396 70.63%, 95.64%, and 0.80, respectively. The exact P-values were as follows: childhood trauma

397 (P=8.72×10^{-11}), family history of PSB (P=3.43×10^{-12}), and gender (men, P<2.00×10^{-16}). Power

398 analysis demonstrated that the regression model had a power of over 0.90. *Abbreviation: PSB:*

399 *problematic sexual behavior; SLC6A3: solute carrier family 6 member 3; VIF: variance inflation*

400 *factor.*

CONFIDENTIAL

401 **Figure 3. Forest Plot of Reward Deficiency Syndrome (RDS) Logistic Regression Analysis**

402 **in Patients and Comparison Participants**

403



404

405 By logistic regression. The log likelihood of the model was -624.29 (n=1044, after removed 282

406 outliers, with 91 of them being RDS positive, a pseudo R^2=0.13, P<0.001). The model passed the

407 link test with a significant P(hat) (P<0.001) and a nonsignificant P (hatsq) (P=0.81). The

408 probability of the Hosmer-Lemeshow $\chi 2$ test was insignificant (P=0.99), suggesting a good

409 model fit. The mean VIF and the condition number were 2.49 and 10.03, respectively. The model

410 accuracy, area under the ROC curve, sensitivity, specificity, and F score were 68.29%, 72.00%,

411 67.46%, 69.16%, and 0.71, respectively. The exact P-values were as follows: the interaction term

412 of 10/10 genotype and childhood trauma (P=3.68×10^{-4}), the 10/10 genotype of *SLC6A3* 3'

413 VNTR (P=1.73×10^{-4}), self-reported mental health condition(s) (P=1.46×10^{-10}), childhood

414 trauma (P=3.88×10^{-5}) and being PSB patients (P<2.00×10^{-16}). Power analysis demonstrated that

415 the regression model had a power of over 0.90. *Abbreviation: PSB: problematic sexual behavior;*

416 *SLC6A3: solute carrier family 6 member 3; VIF: variance inflation factor.*

CONFIDENTIAL

417 **Table 1. Demographic and Clinical Variables across Subgroups: Scores Indicate Median (Ranges) or Frequencies**

418 **(Percentages)**

Variables		**Comparison participants without PSB (n=266-448)**	**Comparison participants with PSB (n=55-89)**	**PSB Patients (n=418-434)**
Age *		23 (18-55) [a]	22 (18-66) [a]	43 (19-80) [b]
Gender *	Women	309 (69.8%)	35 (42.2%)	23 (6.3%)
	Men	134 (30.2%)	50 (58.8%)	408 (94.7%)
SLC6A3 genotype, *P*=0.100	9/9 and 9/10	210 (46.9%)	35 (39.3%)	209 (48.2%)
	10/10	228 (50.9%)	54 (60.7%)	209 (48.2%)
	Rare	10 (2.2%)	0 (0%)	16 (3.6%)
Problematic Sexual Behavior - adjusted SAST-R core *		0 (0-5) [a]	7 (4-18) [b]	15 (10-18) [c]
Relationship disturbance *		0 (0-2) [a]	1 (0-4) [b]	4 (0-4) [c]
Loss of control *		0 (0-2) [a]	2 (0-4) [b]	4 (0-4) [c]
Preoccupation *		0 (0-3) [a]	1 (0-4) [b]	2 (0-4) [c]

CONFIDENTIAL

Variables	Comparison participants without PSB (n=266-448)	Comparison participants with PSB (n=55-89)	PSB Patients (n=418-434)
Affect disturbance *	0 (0-3) [a]	3 (1-5) [b]	4 (2-5) [c]
Reward deficiency syndrome *	0 (0%)	60 (67.4%)	318(84.1%)
FTND *	0 (0-1) [a]	0 (0-7) [b]	0 (0-12)[b]
DPGDF (P=0.051)	0 (0-3) [a]	0 (0-9) [b]	0 (0-9)[b]
SA-SAPAS *	1 (0-3) [a]	1 (0-8) [b]	2 (0-8) [c]
ASRS *	1 (0-3) [a]	3 (0-6) [b]	3 (0-6) [b]
RCBS *	10 (6-24) [a]	11 (6-40) [b]	11 (6-42) [b]
IAT *	22 (0-30) [a]	30 (0-62) [b]	38 (0-97) [c]
Childhood trauma *	67 (15.1%)	33 (37.1%)	290 (70.9%)
Self-reported mental health condition(s) *	0 (0%)	24 (27.0%)	277 (65.2%)
Number of self-reported mental health condition(s) *	0 [a]	0 (0-12) [b]	1 (0-9) [c]

CONFIDENTIAL

Variables	Comparison participants without PSB (n=266-448)	Comparison participants with PSB (n=55-89)	PSB Patients (n=418-434)
Number of mental health condition(s) in family history *	3 (0-17) [a]	4 (0-17) [b]	6 (0-24) [c]
Family history of PSB *	17 (3.8%)	19 (21.6)	273 (62.8%)
OCD *	0 (0%)	8 (9.0%)	61 (14.1%)

*: significant omnibus effect (P<0.001)

[a,b,c]: different superscripts denote significant differences ($P < 0.05$) between groups

Kruskal-Wallis H test and Dunn's post-hoc tests for continuous variables; Pearson's or Fisher's χ^2 test (cells < 5) for categorical variables; Abbreviations: *PSB: problematic sexual behavior; SAST-R: Sexual Addiction Screening Test-Revised; ASRS: Adult ADHD Self-Report Scale version 1.1; FTND: Fagerström Test for Nicotine Dependence; IAT: Internet Addiction Test; OCD: obsessive-compulsive disorder; RCBS: Richmond Compulsive Buying Scale*

CONFIDENTIAL

428 **Table 2. Distribution of Demographic and Clinical Variables by *Solute Carrier Family 6 Member 3 (SLC6A3)* Genotypic**

429 **Group: Scores Indicate Median (Ranges) or Frequencies (Percentages)**

Variables	**Comparison participants (n= 55-89 with PSB; n=266-438 without PSB)**		**PSB patients (391-418) and comparison participants without PSB (n=266-438)**		
	9/9 and 9/10 genotypes)	**10/10 genotype**	**9/9 and 9/10 genotypes**	**10/10 genotype**	**Rare genotypes**
PSB	*30 (12.2%)*†	*52 (18.4%)*†	200 (48.1%)	202 (46.1%)	16 (61.5%)
Adjusted SAST-R core	1 (0-14)	1 (0-18)	4.5 (0-18)	3 (0-18)	12.5 (0-18)
Relationship disturbance	0 (0-3)	0 (0-4)	3 (0-4)	3 (0-4)	3 (0-4)
Loss of control	0 (0-4)	0 (0-4)	2 (0-4)	1 (0-4)	3 (0-4)
Preoccupation	0 (0-4)	0 (0-4)	1 (0-4)	1 (0-4)	1.5 (0-4)
Affect disturbance	0 (0-4)	0 (0-5)	2 (0-5)	2 (0-5)	4 (0-5)
Reward deficiency syndrome	*21 (8.6%)*†	*39 (13.8%)*†	155 (38.3%)	152 (36.4%)	11(45.8%)
FTND	0 (0-4)	0 (0-7)	0 (0-12)	0 (0-11)	0 (0-4)
DPGDF	0 (0-9)	0 (0-9)	0 (0-8)	0 (0-9)	0 (0-3)

CONFIDENTIAL

Variables	Comparison participants (n= 55-89 with PSB; n=266-438 without PSB)		PSB patients (391-418) and comparison participants without PSB (n=266-438)		
	9/9 and 9/10 genotypes)	**10/10 genotype**	**9/9 and 9/10 genotypes**	**10/10 genotype**	**Rare genotypes**
SA-SAPAS	1 (0-7)	1 (0-8)	1 (0-8)	1 (0-8)	1 (0-6)
ASRS	**1 (0-6)***	**1 (0-6)***	2 (0-6)	2 (0-6)	1 (0-6)
RCBS	**10 (6-30)***	**10 (6-40)***	10 (6-32)	10 (6-32)	10 (6-42)
IAT	**22 (0-55)***	**24 (2-62)***	25 (0-89)	26 (1-97)	28 (4-88)
Childhood trauma	45 (18.4%)	55 (19.7%)	169 (41.7%)	176 (41.7%)	12 (46.1%)
Self-reported mental health condition(s)	*7 (2.9%)†*	*17 (6.0%)†*	131 (31.7%)	134 (30.9%)	12 (48.0%)
Number of self-reported mental health condition(s)	*0 (0-10)†*	*0 (0-12)†*	0 (0-6)	0 (0-9)	0 (0-9)
Number of mental health condition(s) in family history	3 (0-17)	3 (0-17)	4 (0-24)	4 (0-19)	4.5 (0-14)
Family history of PSB	15 (6.1%)	21 (7.5%)	142 (33.9%)	138 (31.6%)	10 (38.5%)

CONFIDENTIAL

Variables	Comparison participants (n= 55-89 with PSB; n=266-438 without PSB)		PSB patients (391-418) and comparison participants without PSB (n=266-438)		
	9/9 and 9/10 genotypes)	**10/10 genotype**	**9/9 and 9/10 genotypes**	**10/10 genotype**	**Rare genotypes**
OCD	3 (1.2%)	5 (1.8%)	**27 (6.5%)***	**29 (6.6%)***	**5 (19.2%)***

430

431 *: ***P*<0.05;** †: *P<0.1*

432 Mann-Whitney *U* test for two-group comparisons of continuous variables; Kruskal-Wallis *H* test and Dunn's post-hoc tests for three-
433 group comparisons of continuous variables; Pearson's or Fisher's χ^2 test (cells < 5) for categorical variables; Abbreviations: *PSB:*
434 *problematic sexual behavior; SAST-R: Sexual Addiction Screening Test-Revised; ASRS: Adult ADHD Self-Report Scale version 1.1;*
435 *FTND: Fagerström Test for Nicotine Dependence; IAT: Internet Addiction Test; OCD: obsessive-compulsive disorder; RCBS:*
436 *Richmond Compulsive Buying Scale*

CONFIDENTIAL

437 References

438 1. Jiang S, Wallace K, Yang E, et al. Logistic Regression With Machine Learning Sheds
439 Light on the Problematic Sexual Behavior Phenotype. *J Addict Med*. Mar-Apr 01
440 2023;17(2):174-181. doi:https://doi.org/10.1097/ADM.0000000000001078

441 2. Carnes P. *Don't call it love: Recovery from sexual addiction*. Bantam Books; 1991:439 p.

442 3. Kuzma JM, Black DW. Epidemiology, prevalence, and natural history of compulsive
443 sexual behavior. *Psychiatr Clin North Am*. Dec *2008*;*31*(*4*):603-11.
444 doi:https://10.1016/j.psc.2008.06.005

445 4. Blum K, Braverman ER, Holder JM, et al. The Reward deficiency syndrome: a
446 biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive
447 behaviors. *J Psychoactive Drugs*. Nov 2000;32:1-112.
448 doi:http://doi.org/10.1080/02791072.2000.10736099

449 5. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral
450 disorders. *Prog Brain Res*. 2000/01/01 2000;126:325-341. doi:https://doi.org/10.1016/S0079-
451 6123(00)26022-6

452 6. Blum K, Gold M, Demetrovics Z, et al. Substance use disorder a bio-directional subset of
453 reward deficiency syndrome. *Front Biosci (Landmark Ed)*. Jun 1 2017;22(9):1534-1548.
454 doi:http://doi.org/10.2741/4557

455 7. Gondre-Lewis MC, Bassey R, Blum K. Pre-clinical models of reward deficiency
456 syndrome: A behavioral octopus. *Neurosci Biobehav Rev*. Aug 2020;115:164-188.
457 doi:https://doi.org/10.1016/j.neubiorev.2020.04.021

458 8. Blum K, Dennen CA, Elman I, et al. Should Reward Deficiency Syndrome (RDS) Be
459 Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic
460 Induced Dysregulation of Brain Reward Circuitry? *J Pers Med*. 2022;12(10):1719.
461 doi:http://doi.org/10.3390/jpm12101719

462 9. Blum K, Baron D, McLaughlin TP, Giordano J, Ceccanti MD, Badgaiyan R. Summary
463 document research on RDS anti-addiction modeling: annotated bibliography. *J Addict*
464 *Psychiatry*. 2024;8(1):1-33.

465 10. Ma Y, Yuan W, Cui W, Li MD. Meta-analysis reveals significant association of 3'-UTR
466 VNTR in SLC6A3 with smoking cessation in Caucasian populations. *Pharmacogenomics J*. Feb
467 2016;16(1):10-7. doi:http://doi.org/10.1038/tpj.2015.44

468 11. Franklin TR, Lohoff FW, Wang Z, et al. DAT genotype modulates brain and behavioral
469 responses elicited by cigarette cues. *Neuropsychopharmacology*. Feb 2009;34(3):717-28.
470 doi:https://doi.org/10.1038/npp.2008.124

471 12. Reith MEA, Kortagere S, Wiers CE, et al. The dopamine transporter gene SLC6A3:
472 multidisease risks. *Mol Psychiatry*. Feb 2022;27(2):1031-1046.
473 doi:http://doi.org/10.1038/s41380-021-01341-5

CONFIDENTIAL

13. Schneider JP, M.A. M. Couple recovery from sexual addiction / co addiction: Results of a survey of 88 marriages. *Sexual Addiction and Compulsivity: The Journal of Treatment and Prevention*. 1996;3:111-126.

14. Vandenbergh DJ, Persico AM, Hawkins AL, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. *Genomics*. *Dec* 1992;14(4):1104-6. doi:https://10.1016/s0888-7543(05)80138-7

15. Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Variation in dopamine genes influences responsivity of the human reward system. *Proc Natl Acad Sci U S A*. Jan 13 *2009*;*106*(*2*):617-22. doi:https://doi.org/10.1073/pnas.0805517106

16. Vandenbergh DJ, Persico AM, Uhl GR. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. *Brain Res Mol Brain Res*. Sep 1992;15(1-2):161-6. doi:https://10.1016/0169-328x(92)90165-8

17. Salatino-Oliveira A, Rohde LA, Hutz MH. The dopamine transporter role in psychiatric phenotypes. *Am J Med Genet B Neuropsychiatr Genet*. Mar 2018;177(2):211-231. doi:http://doi.org/10.1002/ajmg.b.32578

18. Volkow ND, Wang G-J, Newcorn JH, et al. Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. *Mol Psychiatry*. 2011;16(11):1147-1154. doi:http://doi.org/10.1038/mp.2010.97

19. Cornish KM, Manly T, Savage R, et al. Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample. *Mol Psychiatry*. Jul 2005;10(7):686-98. doi:https://10.1038/sj.mp.4001641

20. Guo G, Tong Y, Xie C-W, Lange LA. Dopamine transporter, gender, and number of sexual partners among young adults. *Eur J Hum Genet*. 2007;15(3):279-287. doi:http://doi.org/10.1038/sj.ejhg.5201763

21. Guo G, Tong Y, Cai T. Gene by social context interactions for number of sexual partners among white male youths: Genetics-informed sociology. *Am J Sociol*. 2008;114(S1):S36-S66. doi:https://doi.org/10.1086/592207

22. Erblich J, Lerman C, Self DW, Diaz GA, Bovbjerg DH. Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms. *Pharmacogenomics J*. 2004/04/01 2004;4(2):102-9. doi:https://doi.org/10.1038/sj.tpj.6500227

23. Jiang Z, Chen Z, Chen X. Candidate gene-environment interactions in substance abuse: A systematic review. *Plos one*. 2023;18(10):e0287446. doi:http://doi.org/10.1371/journal.pone.0287446.

24. Andreassen OA, Hindley GFL, Frei O, Smeland OB. New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications. *World Psychiatry*. Feb 2023;22(1):4-24. doi:http://doi.org/10.1002/wps.21034

25. Sery O, Paclt I, Drtilkova I, et al. A 40-bp VNTR polymorphism in the 3'-untranslated region of DAT1/SLC6A3 is associated with ADHD but not with alcoholism. *Behav Brain Funct*. Jun 11 2015;11:21. doi:https://doi.org/10.1186%2Fs12993-015-0066-8

CONFIDENTIAL

514 26. Doucette-Stamm LA, Blakely DJ, Tian J, Mockus S, Mao JI. Population genetic study of
515 the human dopamine transporter gene (DAT1). *Genet Epidemiol*. 1995;12(3):303-8.
516 doi:https://doi.org/10.1002/gepi.1370120307

517 27. Carnes P, Green B, Carnes S. The same yet different: Refocusing the Sexual Addiction
518 Screening Test (SAST) to reflect orientation and gender. *Sexual Addiction & Compulsivity*.
519 2010;17(1):7-30. doi:https://doi.org/10.1080/10720161003604087

520 28. *Stata Statistical Software: Release 17*. StataCorp LLC.; 2023.

521 29. Giordano AL, Hedden LE, Kim SW, Lundeen LA, Lu Z. Childhood trauma and sex
522 addiction among adult men. *J Addict Offender Couns*.
523 2024;doi:https://doi.org/10.1002/jaoc.12134

524 30. Franke B, Buitelaar JK. Gene-environment interactions. *Oxford Textbook of Attention*
525 *Deficit Hyperactivity Disorder*. 2018:35.

526 31. Lahey BB, Rathouz PJ, Lee SS, et al. Interactions Between Early Parenting and a
527 Polymorphism of the Child's Dopamine Transporter Gene in Predicting Future Child Conduct
528 Disorder Symptoms. *J Abnorm Psychol*. Feb 2011;120(1):33-45.
529 doi:http://doi.org/10.1037/a0021133

530 32. Kraus SW, Voon V, Potenza MN. Should compulsive sexual behavior be considered an
531 addiction? https://doi.org/10.1111/add.13297. *Addiction*. Dec 2016;111(12):2097-2106.
532 doi:10.1111/add.13297

533 33. Walton MT, Bhullar N. Compulsive Sexual Behavior as an Impulse Control Disorder:
534 Awaiting Field Studies Data. *Arch Sex Behav*. 2018/07/01 2018;47(5):1327-1331.
535 doi:http://doi.org/10.1007/s10508-018-1200-0

536 34. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. *Lancet*
537 *Psychiatry*. Aug 2016;3(8):760-773. doi:https://10.1016/S2215-0366(16)00104-8

538 35. Riemersma J, Sytsma M. A new generation of sexual addiction. *Sexual Addiction &*
539 *Compulsivity*. 2013;20(4):306-322.

540 36. Schmidt C, Morris LS, Kvamme TL, Hall P, Birchard T, Voon V. Compulsive sexual
541 behavior: Prefrontal and limbic volume and interactions. *Hum Brain Mapp*. Mar
542 2017;38(3):1182-1190. doi:https://doi.org/10.1002/hbm.23447

543 37. Billett E, Richter M, Sam F, et al. Investigation of dopamine system genes in obsessive-
544 compulsive disorder. *Psychiatric genetics*. 1998;8(3):163-170.

545 38. Hemmingsa SMJ, Kinnear CJ, Niehaus DJH, et al. Investigating the role of dopaminergic
546 and serotonergic candidate genes in obsessive-compulsive disorder. *Eur Neuropsychopharmacol*.
547 2003/03/01/ 2003;13(2):93-98. doi:https://doi.org/10.1016/S0924-977X(02)00129-3

548 39. Grunblatt E, Werling AM, Roth A, Romanos M, Walitza S. Association study and a
549 systematic meta-analysis of the VNTR polymorphism in the 3'-UTR of dopamine transporter
550 gene and attention-deficit hyperactivity disorder. *J Neural Transm (Vienna)*. Apr
551 2019;126(4):517-529. doi:http://doi.org/10.1007/s00702-019-01998-x

552

CONFIDENTIAL